Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 79Breast Neoplasms 7Neoplasms 6Prostate Adenocarcinoma 2Polycystic Ovary Syndrome 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leiomyoma 2Hodgkin Disease 2Uveal Melanoma 1Urogenital Neoplasms 1Sleep Apnea, Obstructive 1Skin Neoplasms 1Recurrence 1Prostatic Diseases 1Premenopausal Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1PSA Level Greater Than Two 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms, Glandular and Epithelial 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Metabolic Syndrome 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphatic Metastasis 1Lower Urinary Tract Symptoms 1Leukemia, Myelomonocytic, Chronic 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hormone Sensitive Prostate Cancer × Leuprolide × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡